» Articles » PMID: 38393619

Toxicometabolomics-based Cardiotoxicity Evaluation of Thiazolidinedione Exposure in Human-derived Cardiomyocytes

Overview
Journal Metabolomics
Publisher Springer
Specialty Endocrinology
Date 2024 Feb 23
PMID 38393619
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Thiazolidinediones (TZDs), represented by pioglitazone and rosiglitazone, are a class of cost-effective oral antidiabetic agents posing a marginal hypoglycaemia risk. Nevertheless, observations of heart failure have hindered the clinical use of both therapies.

Objective: Since the mechanism of TZD-induced heart failure remains largely uncharacterised, this study aimed to explore the as-yet-unidentified mechanisms underpinning TZD cardiotoxicity using a toxicometabolomics approach.

Methods: The present investigation included an untargeted liquid chromatography-mass spectrometry-based toxicometabolomics pipeline, followed by multivariate statistics and pathway analyses to elucidate the mechanism(s)of TZD-induced cardiotoxicity using AC16 human cardiomyocytes as a model, and to identify the prognostic features associated with such effects.

Results: Acute administration of either TZD agent resulted in a significant modulation in carnitine content, reflecting potential disruption of the mitochondrial carnitine shuttle. Furthermore, perturbations were noted in purine metabolism and amino acid fingerprints, strongly conveying aberrations in cardiac energetics associated with TZD usage. Analysis of our findings also highlighted alterations in polyamine (spermine and spermidine) and amino acid (L-tyrosine and valine) metabolism, known modulators of cardiac hypertrophy, suggesting a potential link to TZD cardiotoxicity that necessitates further research. In addition, this comprehensive study identified two groupings - (i) valine and creatine, and (ii) L-tryptophan and L-methionine - that were significantly enriched in the above-mentioned mechanisms, emerging as potential fingerprint biomarkers for pioglitazone and rosiglitazone cardiotoxicity, respectively.

Conclusion: These findings demonstrate the utility of toxicometabolomics in elaborating on mechanisms of drug toxicity and identifying potential biomarkers, thus encouraging its application in the toxicological sciences. (245 words).

Citing Articles

AMD1, a cardiotoxicity target for Maduramicin.

Xie Z, Liu H, Zhao J, Gao Y, Zhao Y, Zheng J BMC Pharmacol Toxicol. 2025; 26(1):55.

PMID: 40069794 PMC: 11895246. DOI: 10.1186/s40360-025-00897-0.


Integrative analysis of toxicometabolomics and toxicoproteomics data: new molecular insights into thiazolidinedione-induced cardiotoxicity.

Al Sultan A, Rattray Z, Rattray N Metabolomics. 2024; 21(1):1.

PMID: 39636558 PMC: 11621136. DOI: 10.1007/s11306-024-02201-3.


enhances the immunosuppressive milieu of adipose tissue and suppresses fasting blood glucose.

Kobayashi K, Tanabe A, Sasaki K Biomed Rep. 2024; 21(5):164.

PMID: 39268403 PMC: 11391171. DOI: 10.3892/br.2024.1852.

References
1.
DeFronzo R, Inzucchi S, Abdul-Ghani M, Nissen S . Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019; 16(2):133-143. DOI: 10.1177/1479164118825376. View

2.
Yu L, Li H, Zhang C, Zhang Q, Guo J, Li J . Integrating in vitro testing and physiologically-based pharmacokinetic (PBPK) modelling for chemical liver toxicity assessment-A case study of troglitazone. Environ Toxicol Pharmacol. 2019; 74:103296. DOI: 10.1016/j.etap.2019.103296. View

3.
Chaudhury A, Duvoor C, Dendi V, Kraleti S, Chada A, Ravilla R . Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Front Endocrinol (Lausanne). 2017; 8:6. PMC: 5256065. DOI: 10.3389/fendo.2017.00006. View

4.
Nguyen N, Jennen D, Kleinjans J . Omics technologies to understand drug toxicity mechanisms. Drug Discov Today. 2022; 27(11):103348. DOI: 10.1016/j.drudis.2022.103348. View

5.
Schenkl C, Heyne E, Doenst T, Schulze P, Nguyen T . Targeting Mitochondrial Metabolism to Save the Failing Heart. Life (Basel). 2023; 13(4). PMC: 10143865. DOI: 10.3390/life13041027. View